ProQR Q2 revenue and EPS miss estimates

ProQR Therapeutics NV

07/08/2025 12:08

Overview

ProQR Q2 revenue and EPS miss analysts' expectations, per LSEG data

Co submitted CTA for AX-0810, targeting NTCP for cholestatic diseases

ProQR holds EUR119.8 mln cash, providing runway into mid-2027

Outlook

ProQR expects initial AX-0810 Phase 1 data in Q4 2025

Company anticipates AX-2402 clinical candidate selection in 2025

ProQR's cash runway extends into mid-2027, excluding Lilly milestones

Result Drivers

LILLY PARTNERSHIP - Achieved milestones in collaboration with Eli Lilly, contributing €1.8 mln to revenue

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
EUR 3.82 mln
EUR 4.45 mln (7 Analysts)
Q2 EPS
Miss
-EUR 0.12
-EUR 0.08 (7 Analysts)
Q2 Net Income
Miss
-EUR 12.18 mln
-EUR 8.99 mln (6 Analysts)
Q2 Operating Income
Miss
-EUR 12.25 mln
-EUR 8.77 mln (5 Analysts)
Q2 Basic EPS
-EUR 0.12


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for ProQR Therapeutics NV is $9.00, about 77.1% above its August 6 closing price of $2.06

Press Release: ID:nGNE8yKjqm

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)